Rationale: Intravenous administration of the selective serotonin re-uptake inhibitor, citalopram (20 mg), is known to increase plasma
prolactin (PRL) and cortisol in human subjects. This suggests that citalopram may be a useful tool to probe brain serotonin
function.
Objective: To find out whether lower doses of intravenous citalopram would be sufficient to increase plasma prolactin and cortisol.
Methods: Eleven subjects were tested on three occasions in a double-blind, cross-over design receiving: (a) placebo, (b) citalopram
5 mg and (c) citalopram 10 mg infused intravenously over a 30-min period. A further six subjects received intravenous citalopram
(10 mg) on two occasions receiving in addition the 5-HT
2A/2C receptor antagonist, cyproheptadine (4 mg orally) or placebo, 6 h before each infusion in a double-blind, randomised, cross-over
design. Plasma PRL and cortisol levels were measured before and for 150 min after the infusion.
Results: Citalopram increased plasma PRL and cortisol in a dose-related manner. Cyproheptadine lowered baseline PRL and cortisol but
did not attenuate the endocrine responses to citalopram. Citalopram infusions were well-tolerated.
Conclusions: Low-dose citalopram has potential utility as a neuroendocrine challenge test. The endocrine responses to citalopram are probably
not mediated predominantly by 5-HT
2A/2C receptors.
Citalopram Prolactin Cortisol Serotonin 5-HT2 receptor
Electronic Publication